Additional Relevant Details The FDA approved Roche's Gazyva (obinutuzumab) to treat people with follicular lymphoma.  This is the second FDA approval for Gazyva and Gazyva is now approved in the United States to treat two common types of blood cancer.   Marketing applications have also been submitted to other regulatory agencies including the European Medicines Agency.